Matinas BioPharma Files 8-K on Shareholder Vote
Ticker: MTNB · Form: 8-K · Filed: Apr 4, 2025 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | 8-K |
| Filed Date | Apr 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
TL;DR
Matinas BioPharma is having a shareholder vote, details to follow.
AI Summary
Matinas BioPharma Holdings, Inc. filed an 8-K on April 4, 2025, reporting on the submission of matters to a vote of security holders. The filing does not contain specific details about the vote itself, such as proposals or outcomes, but indicates that a shareholder vote is scheduled or has occurred.
Why It Matters
This filing signals that important corporate decisions are being put to a vote by Matinas BioPharma's shareholders, which could impact the company's future direction.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Registrant
- April 4, 2025 (date) — Date of earliest event reported
FAQ
What specific matters are being submitted to a vote of Matinas BioPharma's security holders?
The filing does not specify the exact matters being submitted for a vote, only that such submissions are occurring.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on April 4, 2025.
What is the principal executive office address for Matinas BioPharma Holdings, Inc.?
The principal executive offices are located at 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921.
What is the IRS Employer ID Number for Matinas BioPharma Holdings, Inc.?
The IRS Employer ID Number is 46-3011414.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 4, 2025 regarding Matinas BioPharma Holdings, Inc. (MTNB).